National Pension Service Has $108.47 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

National Pension Service boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 874,115 shares of the medical device company’s stock after purchasing an additional 22,931 shares during the period. National Pension Service’s holdings in DexCom were worth $108,469,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Valley National Advisers Inc. lifted its holdings in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. MV Capital Management Inc. lifted its stake in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Washington Trust Advisors Inc. grew its position in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after acquiring an additional 193 shares in the last quarter. NBC Securities Inc. acquired a new position in shares of DexCom during the 3rd quarter worth $47,000. Finally, Thompson Siegel & Walmsley LLC bought a new position in shares of DexCom during the 3rd quarter valued at $48,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on DXCM shares. UBS Group upped their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Citigroup upped their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. Finally, Raymond James boosted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $141.67.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $2.68 on Wednesday, hitting $127.42. 1,336,567 shares of the company were exchanged, compared to its average volume of 2,981,269. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The company’s 50 day moving average price is $132.94 and its two-hundred day moving average price is $121.16. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00. The firm has a market capitalization of $50.67 billion, a price-to-earnings ratio of 82.21, a PEG ratio of 2.19 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Research analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 629 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the sale, the executive vice president now directly owns 68,212 shares in the company, valued at approximately $8,611,765. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 629 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the sale, the executive vice president now owns 68,212 shares in the company, valued at approximately $8,611,765. The disclosure for this sale can be found here. Insiders sold 190,004 shares of company stock valued at $25,610,270 over the last quarter. Corporate insiders own 0.41% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.